Investigating Exercise in Myotonic Dystrophy Type 2 (DM2)

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-70
SponsorMassachusetts General Hospital

About this trial

An exercise regimen (PRIME: Proximal Resistance In-House Movement Exercise) has been designed for patients with myotonic dystrophy type 2 (DM2). The hypothesis is that this patient-friendly physical therapist (PT)-guided exercise program associates with improved functional capacity and muscle composition in DM2 in this two-period two-sequence cross-over study. Thus, participant will be randomized to one of the three possible groups. Participants in GROUP A will perform exercise routine virtually under the direct supervision of a physical therapist once a week and another session on their own for the first three months, then they will continue with same exercise routine at home for the last 3 months on their own. Participants in GROUP B will perform exercise routine virtually under the direct supervision of a physical therapist twice a week for the first three months, then they will continue with same exercise routine at home for the last 3 months on their own. Participants in GROUP C will perform exercise routine on their own during the first 3 months, then they will perform exercise routine virtually under the direct supervision of a physical therapist. Each group will include around 8 participants. Duration of the study is 6 months. In addition to exercise sessions, participants will have evaluation of their strength, motor function and muscle composition at three time points: initiation, 3 months and completion of the study at 6 months. Muscle composition will be assessed by electrical impedance myography which is a portable, non-invasive, painless and non-radiation tool that applies a weak high multifrequency electrical current to the examined muscle and allows to obtain information about its composition.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients with genetically confirmed myotonic dystrophy 2 (DM2) who are ≥18 and ≤ 70 years old.

Patients are ambulatory without need of any assistance or device.

Patients have a normal ECG within the 3 months prior to Screening visit (of note, patients with DM2 are recommended to have routine ECG as part of patient care. So, this ECG will be done as part of patient care).

Body mass index (BMI) ≥20 and ≤30.

Disqualifiers

Subjects younger than 18 years old or older than 70 years old.

Inability or unwillingness of the subject to give written informed consent.

Subjects with pacemaker.

Blood pressure <90/50 mmHg or >160 mmHg/90 mmHg at Screening visit

Trial design

Design model

Crossover

Treatments tested in this trial

  • Exercise

    Other intervention

    A patient-friendly exercise routine has been designed for patients with myotonic dystrophy type 2. Benefits of this exercise regimen in different settings (at home versus clinic, self-directed versus physical therapist-directed) will be investigated. In person exercise supervised by physical therapist and then self-directed exercise in Group A

  • Exercise

    Other intervention

    Exercise virtually supervised by physical therapist and then self-directed for group B

  • Exercise

    Other intervention

    Self-directed and virtually supervised exercise by physical therapist for Group C

Treatment groups

24 Participants
are divided into 3 treatment groups
Group A: Group AActive comparator 1 intervention
Group B: Group BActive comparator 1 intervention
Group C: Group CActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Manual Muscle Test (MMT)

Score of manual muscle strength test scale. This is a strength exam at bedside of muscle groups

Time frame
From enrollment to the end of treatment at 6 months
2

Six-minute walking test

Distance in meters that subject can walk in six minutes

Time frame
From enrollment to the end of treatment at 6 months

Secondary outcomes

1

Quantitative myometry

Muscle dynamometry of different muscle groups measured in kilograms

Time frame
From enrollment to the end of treatment at 6 months
2

Muscle resistance/reactance measures in ohms

using electrical impedance myography, resistance and reactance measures in ohms will be obtained simultaneously from each examined muscle

Time frame
From enrollment to the end of treatment at 6 months

Other outcomes

1

Time up to go

Time in seconds from standing up, walk 3 meters, come back and sit again.

Time frame
From enrollment to the end of treatment at 6 months
2

10 meter walk testing

Time in seconds during a 10-meter walk.

Time frame
From enrollment to the end of treatment at 6 months
3

Five times sit to stand

Time in seconds to complete 5 times sit to stand.

Time frame
From enrollment to the end of treatment at 6 months
4

Functional gait assessment (FGA)

Assessment of balance using a scale (0-30) while walking and performing motor tasks.

Time frame
From enrollment to the end of treatment at 6 months

Sponsors and contacts

Click on the lead sponsor to view all of their trials.